FRα is the target of the clinically validated IgG antibody‐drug conjugate, mirvetuximab soravtansine, approved for the treatment of ovarian cancers [7, 8, 9, 10, 11, 12, 13]. The gene discussed is FOLR1; the disease is ovarian cancer.